Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
High-risk Prostate Cancer
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male

Other Inclusion Criteria:
1. Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration
2. History/physical examination within 120 days prior to registration
3. Bone imaging within 120 days prior to registration

You may not be eligible for this study if the following are true:

1. Definitive radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI)
2. Prior radical prostatectomy
3. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies